Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin's Lymphoma

Daniar Aspetov, Maria Omarova, Lyazzat Orakbay, Raiymkul Karakulov, Kairat Doskhozhayev, Bayan Zhumatova, Meruyert Chazhayeva
2015 International Journal of Biomedicine  
This study evaluated the effects of the immunobiological preparation "Interferon inducer bacterial liquid" (IIBI) combined with chemoradiotherapy (CRT) in patients with refractory Hodgkin's lymphoma (HL) are presented. The clinical application of IIBI increases the efficacy of treatment. IIBI in combination with CRT induces the production of highly active endogenous IFNα/β, provides a marked regression of the affected lymph nodes in a short period (within 7 to 10 days) of treatment, relieves B
more » ... atment, relieves B symptoms, and increases by 2 times the length of remission in patients with refractory HL. (Int J Biomed. 2015; 5(4):214-218.)
doi:10.21103/article5(4)_oa9 fatcat:jvqaanglm5embi2mpjo727csgm